Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07297212 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 1 → 6 locationsv4
  2. Eligibility criteria expanded, about 23 words Secondary endpoints revised (10) · Study description expanded, about 14 words · Study title expanded, about 1 wordv3 Show 3 more changesShow less
    • Secondary endpoints revised (10)
    • Study description expanded, about 14 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Jan 2026 to Jan 15, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2026 to Jan 15, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
BioNTech SE
49 trials monitored
See 3 trials at risk
Glioblastoma
670 trials monitored
See 44 trials at risk
This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.
Trial Details
NCT Number NCT07297212
Lead Sponsor BioNTech SE
Collaborators: Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Conditions Recurrent Glioblastoma
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov